Matthew C Kiernan

List of Publications by Year in Descending Order

406 papers	17,407 citations	66 h-index	118 g-index
445 ext. papers	21,298 ext. citations	6.7 avg, IF	7 L-index

#	Paper	IF	Citations
406	Functional characterisation of the amyotrophic lateral sclerosis risk locus GPX3/TNIP1.. *Genome Medicine*, **2022**, 14, 7	14.4	0
405	Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS.. *Science Translational Medicine*, **2022**, 14, eabj0264	17.5	4
404	Apathy in amyotrophic lateral sclerosis: systematic review and meta-analysis of frequency, correlates, and outcomes.. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2022**, 1-10	3.6	0
403	Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis.. *Lancet Neurology, The*, **2022**,	24.1	10
402	Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.. *Journal of Neurology, Neurosurgery and Psychiatry*, **2022**,	5.5	4
401	Schizotypal traits across the amyotrophic lateral sclerosis-frontotemporal dementia spectrum: pathomechanistic insights.. *Journal of Neurology*, **2022**, 1	5.5	
400	Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis.. *Lancet Neurology, The*, **2022**,	24.1	8
399	Development and consensus process for a clinical pathway for the assessment and management of chemotherapy-induced peripheral neuropathy.. *Supportive Care in Cancer*, **2022**, 1	3.9	0
398	Consensus for experimental design in electromyography (CEDE) project: High-density surface electromyography matrix.. *Journal of Electromyography and Kinesiology*, **2022**, 64, 102656	2.5	4
397	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. *Nature Genetics*, **2021**, 53, 1636-1648	36.3	19
396	Factors That Influence Non-Motor Impairment Across the ALS-FTD Spectrum: Impact of Phenotype, Sex, Age, Onset and Disease Stage.. *Frontiers in Neurology*, **2021**, 12, 743688	4.1	0
395	Tackling clinical heterogeneity across the amyotrophic lateral sclerosis-frontotemporal dementia spectrum using a transdiagnostic approach. *Brain Communications*, **2021**, 3, fcab257	4.5	1
394	Apathy is associated with parietal cortical-subcortical dysfunction in ALS. *Cortex*, **2021**, 145, 341-349	3.8	5
393	Loss of the metabolism and sleep regulating neuronal populations expressing orexin and oxytocin in the hypothalamus in amyotrophic lateral sclerosis. *Neuropathology and Applied Neurobiology*, **2021**, 47, 979-989	5.2	5
392	Association of Cortical Hyperexcitability and Cognitive Impairment in Patients With Amyotrophic Lateral Sclerosis. *Neurology*, **2021**, 96, e2090-e2097	6.5	1
391	Coexisting Lewy body disease and clinical parkinsonism in amyotrophic lateral sclerosis. *European Journal of Neurology*, **2021**, 28, 2192-2199	6	4
390	Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis. *CNS Drugs*, **2021**, 35, 483-505	6.7	3

389	Genetic analysis of GLT8D1 and ARPP21 in Australian familial and sporadic amyotrophic lateral sclerosis. *Neurobiology of Aging*, **2021**, 101, 297.e9-297.e11	5.6	2
388	Neural correlates of fat preference in frontotemporal dementia: translating insights from the obesity literature. *Annals of Clinical and Translational Neurology*, **2021**, 8, 1318-1329	5.3	1
387	Genetic Analysis of Tryptophan Metabolism Genes in Sporadic Amyotrophic Lateral Sclerosis. *Frontiers in Immunology*, **2021**, 12, 701550	8.4	1
386	Behavioural changes predict poorer survival in amyotrophic lateral sclerosis. *Brain and Cognition*, **2021**, 150, 105710	2.7	4
385	Author Response: Phenotypic Variability in ALS-FTD and Effect on Survival. *Neurology*, **2021**, 96, 1103-1104	6.5	
384	Neural mechanisms of psychosis vulnerability and perceptual abnormalities in the ALS-FTD spectrum. *Annals of Clinical and Translational Neurology*, **2021**, 8, 1576-1591	5.3	3
383	Brainstem Correlates of Pathological Laughter and Crying Frequency in ALS. *Frontiers in Neurology*, **2021**, 12, 704059	4.1	2
382	Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy-a randomised controlled trial. *Supportive Care in Cancer*, **2021**, 29, 1103-1110	3.9	7
381	A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of In Patients With ALS. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2021**, 22, 287-299	3.6	10
380	Pathophysiological associations of transcallosal dysfunction in ALS. *European Journal of Neurology*, **2021**, 28, 1172-1180	6	4
379	Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. *JAMA Neurology*, **2021**, 78, 186-196	17.2	29
378	Improving clinical trial outcomes in amyotrophic lateral sclerosis. *Nature Reviews Neurology*, **2021**, 17, 104-118	15	46
377	Cortical inexcitability defines an adverse clinical profile in amyotrophic lateral sclerosis. *European Journal of Neurology*, **2021**, 28, 90-97	6	3
376	Motor cortical excitability predicts cognitive phenotypes in amyotrophic lateral sclerosis. *Scientific Reports*, **2021**, 11, 2172	4.9	5
375	Neurotoxicity and ALS: Insights into Pathogenesis **2021**, 1-19		
374	Study protocol of RESCUE-ALS: A Phase 2, andomised, double-blind, placebo-controlled study in arly ymptomatic amyotrophic lateral sclerosis patients to assess bioenergetic atalysis with CNM-A8 as a mechanism to slow diseas progression. *BMJ Open*, **2021**, 11, e041479	3	12
373	Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review. *Journal of Cancer Survivorship*, **2021**, 1	5.1	7
372	Diagnostic Utility of Gold Coast Criteria in Amyotrophic Lateral Sclerosis. *Annals of Neurology*, **2021**, 89, 979-986	9.4	20

371	Weekly Paclitaxel-Induced Neurotoxicity in Breast Cancer: Outcomes and Dose Response. *Oncologist*, **2021**, 26, 366-374	5.7	3
370	Mills Syndrome: Clinical and Radiologic Asymmetry. *Neurology*, **2021**, 96, 677-678	6.5	0
369	Nerve biopsy: Current indications and decision tools. *Muscle and Nerve*, **2021**, 64, 125-139	3.4	8
368	The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors. *Journal of Cancer Survivorship*, **2021**, 1	5.1	6
367	Effect of Hemodiafiltration on the Progression of Neuropathy with Kidney Failure: A Randomized Controlled Trial. *Clinical Journal of the American Society of Nephrology: CJASN*, **2021**, 16, 1365-1375	6.9	1
366	Consensus for experimental design in electromyography (CEDE) project: Terminology matrix. *Journal of Electromyography and Kinesiology*, **2021**, 59, 102565	2.5	8
365	Chemotherapy and peripheral neuropathy. *Neurological Sciences*, **2021**, 42, 4109-4121	3.5	4
364	Gold Coast diagnostic criteria: Implications for ALS diagnosis and clinical trial enrollment. *Muscle and Nerve*, **2021**, 64, 532-537	3.4	2
363	Review Article "Spotlight on Ultrasonography in the Diagnosis of Peripheral Nerve Disease: The Evidence to Date". *International Journal of General Medicine*, **2021**, 14, 4579-4604	2.3	0
362	Cortical hyperexcitability: Diagnostic and pathogenic biomarker of ALS. *Neuroscience Letters*, **2021**, 759, 136039	3.3	6
361	Safety and efficacy of dimethyl fumarate in ALS: randomised controlled study. *Annals of Clinical and Translational Neurology*, **2021**, 8, 1991-1999	5.3	2
360	MiNDAUS partnership: a roadmap for the cure and management of motor Neurone disease. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2021**, 1-8	3.6	0
359	Illness Cognitions in ALS: New Insights Into Clinical Management of Behavioural Symptoms. *Frontiers in Neurology*, **2021**, 12, 740693	4.1	
358	Effect of racial background on motor cortical function as measured by threshold tracking transcranial magnetic stimulation. *Journal of Neurophysiology*, **2021**, 126, 840-844	3.2	0
357	Nerve biopsy in acquired neuropathies. *Journal of the Peripheral Nervous System*, **2021**, 26 Suppl 2, S21-S41	4.7	0
356	Diagnostic contribution and therapeutic perspectives of transcranial magnetic stimulation in dementia. *Clinical Neurophysiology*, **2021**, 132, 2568-2607	4.3	16
355	Predictors of survival in frontotemporal lobar degeneration syndromes. *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**,	5.5	3
354	Problem-focused coping underlying lower caregiver burden in ALS-FTD: implications for caregiver intervention. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2021**, 22, 434-441	3.6	0

353	Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial. *Muscle and Nerve*, **2021**, 63, 371-383	3.4	3
352	Differences in nerve excitability properties across upper limb sensory and motor axons.. *Clinical Neurophysiology*, **2021**, 136, 138-149	4.3	0
351	Pathological manifestation of human endogenous retrovirus K in frontotemporal dementia.. *Communications Medicine*, **2021**, 1,		1
350	A Systematic Review of Caregiver Coping Strategies in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.. *Journal of Geriatric Psychiatry and Neurology*, **2021**, 8919887211060016	3.8	0
349	The centenary milestone award 2020. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 677	5.5	1
348	ALS is a multistep process in South Korean, Japanese, and Australian patients. *Neurology*, **2020**, 94, e1657-e1668	7.5	38
347	Interrogating interneurone function using threshold tracking of the H reflex in healthy subjects and patients with motor neurone disease. *Clinical Neurophysiology*, **2020**, 131, 1986-1996	4.3	2
346	Review of the revised amyotrophic lateral sclerosis diagnostic criteria. *Clinical Neurophysiology*, **2020**, 131, 1767-1768	4.3	4
345	Consensus for experimental design in electromyography (CEDE) project: Amplitude normalization matrix. *Journal of Electromyography and Kinesiology*, **2020**, 53, 102438	2.5	64
344	Interneuronal networks mediate cortical inhibition and facilitation. *Clinical Neurophysiology*, **2020**, 131, 1000-1010	4.3	3
343	Genetic and immunopathological analysis of CHCHD10 in Australian amyotrophic lateral sclerosis and frontotemporal dementia and transgenic TDP-43 mice. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 162-171	5.5	4
342	Health, wellbeing and lived experiences of adults with SMA: a scoping systematic review. *Orphanet Journal of Rare Diseases*, **2020**, 15, 70	4.2	14
341	Amyotrophic lateral sclerosis: a new diagnostic paradigm. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 903-904	5.5	1
340	Regional callosal integrity and bilaterality of limb weakness in amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2020**, 21, 396-402	3.6	8
339	The impact of cognitive and behavioral impairment in amyotrophic lateral sclerosis. *Expert Review of Neurotherapeutics*, **2020**, 20, 281-293	4.3	23
338	Taxane-induced peripheral neuropathy: differences in patient report and objective assessment. *Supportive Care in Cancer*, **2020**, 28, 4459-4466	3.9	11
337	Expanding the availability of medications for amyotrophic lateral sclerosis in Australia. *Medical Journal of Australia*, **2020**, 212, 189-189.e1	4	1
336	Occasional essay: Upper motor neuron syndrome in amyotrophic lateral sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 227-234	5.5	14

335	A novel phenotype of hereditary spastic paraplegia type 7 associated with a compound heterozygous mutation in paraplegin. *Muscle and Nerve*, **2020**, 62, E44-E45	3.4	1
334	Subacute sensory neuronopathy and cancer: the identification of paraneoplastic syndromes. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 793-794	5.5	0
333	Electrophysiological and phenotypic profiles of taxane-induced neuropathy. *Clinical Neurophysiology*, **2020**, 131, 1979-1985	4.3	6
332	Cortical hyperexcitability evolves with disease progression in ALS. *Annals of Clinical and Translational Neurology*, **2020**, 7, 733-741	5.3	18
331	Primary lateral sclerosis: consensus diagnostic criteria. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 373-377	5.5	59
330	Phenotypic variability in ALS-FTD and effect on survival. *Neurology*, **2020**, 94, e2005-e2013	6.5	15
329	Transcranial magnetic stimulation in the cortical exploration of dementia **2020**, 327-343		0
328	Neurophysiological features of primary lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2020**, 21, 11-17	3.6	4
327	Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials. *Hematological Oncology*, **2020**, 38, 229-243	1.3	14
326	Early focality and spread of cortical dysfunction in amyotrophic lateral sclerosis: A regional study across the motor cortices. *Clinical Neurophysiology*, **2020**, 131, 958-966	4.3	10
325	Respiratory function and cognitive profile in amyotrophic lateral sclerosis. *European Journal of Neurology*, **2020**, 27, 685-691	6	6
324	Spinal muscular atrophy - the dawning of a new era. *Nature Reviews Neurology*, **2020**, 16, 593-594	15	4
323	Fatal cerebellar oedema in adult Leigh syndrome. *Practical Neurology*, **2020**, 20, 336-337	2.4	1
322	Changes in long term peripheral nerve biophysical properties in childhood cancer survivors following neurotoxic chemotherapy. *Clinical Neurophysiology*, **2020**, 131, 783-790	4.3	3
321	Altered serum protein levels in frontotemporal dementia and amyotrophic lateral sclerosis indicate calcium and immunity dysregulation. *Scientific Reports*, **2020**, 10, 13741	4.9	10
320	Isaacs syndrome: the frontier of neurology, psychiatry, immunology and cancer. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 1243-1244	5.5	5
319	Queen Square: a history of the National Hospital and its Institute of Neurology. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 560-561	5.5	
318	Nerve Pathology Distinguishes Focal Motor Chronic Inflammatory Demyelinating Polyradiculoneuropathy From Multifocal Motor Neuropathy. *Journal of Clinical Neuromuscular Disease*, **2020**, 22, 1-10	1.1	3

317	Identity by descent analysis identifies founder events and links familial and sporadic ALS cases. *Npj Genomic Medicine*, **2020**, 5, 32	6.2	4
316	Jewels in the crown: a century of achievement for the. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 1-2	5.5	4
315	Multifocal motor neuropathy: controversies and priorities. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 140-148	5.5	25
314	Measurement of axonal excitability: Consensus guidelines. *Clinical Neurophysiology*, **2020**, 131, 308-323	4.3	31
313	Quantification of Small Fiber Neuropathy in Chemotherapy-Treated Patients. *Journal of Pain*, **2020**, 21, 44-58	5.2	12
312	Sonographic assessment of nerve blood flow in diabetic neuropathy. *Diabetic Medicine*, **2020**, 37, 343-349	3.5	5
311	A proposal for new diagnostic criteria for ALS. *Clinical Neurophysiology*, **2020**, 131, 1975-1978	4.3	91
310	Evidence for polygenic and oligogenic basis of Australian sporadic amyotrophic lateral sclerosis. *Journal of Medical Genetics*, **2020**,	5.8	16
309	TDP-43 proteinopathies: a new wave of neurodegenerative diseases. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**,	5.5	51
308	Relative contributions of diabetes and chronic kidney disease to neuropathy development in diabetic nephropathy patients. *Clinical Neurophysiology*, **2019**, 130, 2088-2095	4.3	7
307	Vasculitic neuropathy: Comparison of clinical predictors with histopathological outcome. *Muscle and Nerve*, **2019**, 59, 643-649	3.4	9
306	Cerebellar tract alterations in PLS and ALS. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2019**, 20, 281-284	3.6	18
305	Clinical and neuroimaging investigations of language disturbance in frontotemporal dementia-motor neuron disease patients. *Journal of Neurology*, **2019**, 266, 921-933	5.5	11
304	Amyotrophic lateral sclerosis diagnostic index: Toward a personalized diagnosis of ALS. *Neurology*, **2019**, 92, e536-e547	6.5	11
303	Eating peptides: biomarkers of neurodegeneration in amyotrophic lateral sclerosis and frontotemporal dementia. *Annals of Clinical and Translational Neurology*, **2019**, 6, 486-495	5.3	20
302	Amyotrophic lateral sclerosis: Origins traced to impaired balance between neural excitation and inhibition in the neonatal period. *Muscle and Nerve*, **2019**, 60, 232-235	3.4	18
301	Motor neuron disease with malignancy: Clinical and pathophysiological insights. *Clinical Neurophysiology*, **2019**, 130, 1557-1561	4.3	
300	Conduction block in immune-mediated neuropathy: paranodopathy versus axonopathy. *European Journal of Neurology*, **2019**, 26, 1121-1129	6	10

299	Patient Editorial Board for JNNP. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 369-370	5.5	1
298	The effect of coil type and limb dominance in the assessment of lower-limb motor cortex excitability using TMS. *Neuroscience Letters*, **2019**, 699, 84-90	3.3	12
297	Measuring network disruption in neurodegenerative diseases: New approaches using signal analysis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 1011-1020	5.5	21
296	The underacknowledged PPA-ALS: A unique clinicopathologic subtype with strong heritability. *Neurology*, **2019**, 92, e1354-e1366	6.5	19
295	Interrogating cortical function with transcranial magnetic stimulation: insights from neurodegenerative disease and stroke. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 47-57	5.5	17
294	Regional motor cortex dysfunction in amyotrophic lateral sclerosis. *Annals of Clinical and Translational Neurology*, **2019**, 6, 1373-1382	5.3	9
293	CNS cell type-specific gene profiling of P301S tau transgenic mice identifies genes dysregulated by progressive tau accumulation. *Journal of Biological Chemistry*, **2019**, 294, 14149-14162	5.4	6
292	Neuroinflammation in frontotemporal dementia. *Nature Reviews Neurology*, **2019**, 15, 540-555	15	77
291	Recent Developments in TSPO PET Imaging as A Biomarker of Neuroinflammation in Neurodegenerative Disorders. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	97
290	Amyotrophic lateral sclerosis as a multi-step process: an Australia population study. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2019**, 20, 532-537	3.6	13
289	Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2019**, 20, 595-604	3.6	32
288	Consensus for experimental design in electromyography (CEDE) project: Electrode selection matrix. *Journal of Electromyography and Kinesiology*, **2019**, 48, 128-144	2.5	43
287	Inherited Neuropathies. *Seminars in Neurology*, **2019**, 39, 620-639	3.2	5
286	TDP-43 levels in the brain tissue of ALS cases with and without or gene expansions. *Neurology*, **2019**, 93, e1748-e1755	6.5	8
285	Sound of the crowd: wisdom of neurologists revisited. *Practical Neurology*, **2019**, 19, 552	2.4	
284	Neural networks associated with body composition in frontotemporal dementia. *Annals of Clinical and Translational Neurology*, **2019**, 6, 1707-1717	5.3	7
283	009 Axonal excitability properties in dravet syndrome reflect effect of loss of sodium channels. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, A4.1-A4	5.5	
282	COG-01 Phenotypic variation in ?ALS-FTD and effect on survival. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2019**, 20, 301-308	3.6	1

281	Potassium control in chronic kidney disease: implications for neuromuscular function. *Internal Medicine Journal*, **2019**, 49, 817-825	1.6	9
280	Human cerebral evolution and the clinical syndrome of amyotrophic lateral sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 570-575	5.5	7
279	Aerobic exercise training may improve nerve function in type 2 diabetes and pre-diabetes: A systematic review. *Diabetes/Metabolism Research and Reviews*, **2019**, 35, e3099	7.5	7
278	The utility of the Total Neuropathy Score as an instrument to assess neuropathy severity in chronic kidney disease: A validation study. *Clinical Neurophysiology*, **2018**, 129, 889-894	4.3	7
277	Inter-session reliability of short-interval intracortical inhibition measured by threshold tracking TMS. *Neuroscience Letters*, **2018**, 674, 18-23	3.3	22
276	Implications of structural and functional brain changes in amyotrophic lateral sclerosis. *Expert Review of Neurotherapeutics*, **2018**, 18, 407-419	4.3	11
275	Excitability of sensory axons in amyotrophic lateral sclerosis. *Clinical Neurophysiology*, **2018**, 129, 1472-1478	4.3	5
274	Ectopic impulse generation in peripheral nerve hyperexcitability syndromes and amyotrophic lateral sclerosis. *Clinical Neurophysiology*, **2018**, 129, 974-980	4.3	11
273	Tracking small sensory nerve action potentials in human axonal excitability studies. *Journal of Neuroscience Methods*, **2018**, 298, 45-53	3	10
272	Structural and functional papez circuit integrity in amyotrophic lateral sclerosis. *Brain Imaging and Behavior*, **2018**, 12, 1622-1630	4.1	17
271	Motor neuron disease in 2017: Progress towards therapy in motor neuron disease. *Nature Reviews Neurology*, **2018**, 14, 65-66	15	15
270	Stimulus, response and excitability - What is new?. *Clinical Neurophysiology*, **2018**, 129, 333-334	4.3	3
269	Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies. *Brain*, **2018**, 141, 521-534	11.2	84
268	Selective Spatiotemporal Vulnerability of Central Nervous System Neurons to Pathologic TAR DNA-Binding Protein 43 in Aged Transgenic Mice. *American Journal of Pathology*, **2018**, 188, 1447-1456	5.8	6
267	Physiological changes in neurodegeneration - mechanistic insights and clinical utility. *Nature Reviews Neurology*, **2018**, 14, 259-271	15	51
266	Riluzole, disease stage and survival in ALS. *Lancet Neurology, The*, **2018**, 17, 385-386	24.1	67
265	Effects of hemodialysis on intraneural blood flow in end-stage kidney disease. *Muscle and Nerve*, **2018**, 57, 287-293	3.4	5
264	Multimodal quantitative examination of nerve function in colorectal cancer patients prior to chemotherapy. *Muscle and Nerve*, **2018**, 57, 615-621	3.4	2

263	Cortical excitability varies across different muscles. *Journal of Neurophysiology*, **2018**, 120, 1397-1403	3.2	7
262	Regional thalamic MRI as a marker of widespread cortical pathology and progressive frontotemporal involvement in amyotrophic lateral sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2018**, 89, 1250-1258	5.5	25
261	Fasciculation intensity and disease progression in amyotrophic lateral sclerosis. *Clinical Neurophysiology*, **2018**, 129, 2149-2154	4.3	14
260	Physiological Processes Underlying Short Interval Intracortical Facilitation in the Human Motor Cortex. *Frontiers in Neuroscience*, **2018**, 12, 240	5.1	20
259	Comparison of cross-sectional areas and distal-proximal nerve ratios in amyotrophic lateral sclerosis. *Muscle and Nerve*, **2018**, 58, 777-783	3.4	15
258	Anti-MAG neuropathy: Role of IgM antibodies, the paranodal junction and juxtaparanodal potassium channels. *Clinical Neurophysiology*, **2018**, 129, 2162-2169	4.3	9
257	Correlation between markers of peripheral nerve function and structure in type 1 diabetes. *Diabetes/Metabolism Research and Reviews*, **2018**, 34, e3028	7.5	15
256	Primary lateral sclerosis and the amyotrophic lateral sclerosis-frontotemporal dementia spectrum. *Journal of Neurology*, **2018**, 265, 1819-1828	5.5	24
255	A unified model of the excitability of mouse sensory and motor axons. *Journal of the Peripheral Nervous System*, **2018**, 23, 159-173	4.7	8
254	Lipid Metabolism and Survival Across the Frontotemporal Dementia-Amyotrophic Lateral Sclerosis Spectrum: Relationships to Eating Behavior and Cognition. *Journal of Alzheimeris Disease*, **2018**, 61, 773-783	4.3	35
253	Functional Biomarkers for Amyotrophic Lateral Sclerosis. *Frontiers in Neurology*, **2018**, 9, 1141	4.1	17
252	Kinnier Wilson's puzzling features of amyotrophic lateral sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2018**, 89, 657-666	5.5	3
251	Neurofascin-155 IGG4 Neuropathy: Pathophysiological Insights, Spectrum of Clinical Severity and Response To treatment. *Muscle and Nerve*, **2018**, 57, 848-851	3.4	25
250	Motor neurone disease. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2018**, 159, 345-357	3	6
249	Frontostriatal grey matter atrophy in amyotrophic lateral sclerosis A visual rating study. *Dementia E Neuropsychologia*, **2018**, 12, 388-393	2.1	1
248	Utility of threshold tracking transcranial magnetic stimulation in ALS. *Clinical Neurophysiology Practice*, **2018**, 3, 164-172	3.8	29
247	Psychiatric disorders in kindreds: Study of 1,414 family members. *Neurology*, **2018**, 91, e1498-e1507	6.5	50
246	Imbalance of cortical facilitatory and inhibitory circuits underlies hyperexcitability in ALS. *Neurology* , **2018**, 91, e1669-e1676	6.5	41

245	The burden of apathy for caregivers of patients with amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2018**, 19, 599-605	3.6	17
244	Association of Leucine-Rich Glioma Inactivated Protein 1, Contactin-Associated Protein 2, and Contactin 2 Antibodies With Clinical Features and Patient-Reported Pain in Acquired Neuromyotonia. *JAMA Neurology*, **2018**, 75, 1519-1527	17.2	31
243	In vivo evidence for reduced ion channel expression in motor axons of patients with amyotrophic lateral sclerosis. *Journal of Physiology*, **2018**, 596, 5379-5396	3.9	10
242	Neural correlates of changes in sexual function in frontotemporal dementia: implications for reward and physiological functioning. *Journal of Neurology*, **2018**, 265, 2562-2572	5.5	10
241	Chemotherapy-Induced Peripheral Neuropathy in Long-term Survivors of Childhood Cancer: Clinical, Neurophysiological, Functional, and Patient-Reported Outcomes. *JAMA Neurology*, **2018**, 75, 980-988	17.2	47
240	Inflammatory neuropathies: all shapes and sizes. *Journal of Neurology, Neurosurgery and Psychiatry*, **2018**, 89, 1128	5.5	
239	Utility of maximum perfusion intensity as an ultrasonographic marker of intraneural blood flow. *Muscle and Nerve*, **2017**, 55, 77-83	3.4	18
238	Differentiating lower motor neuron syndromes. *Journal of Neurology, Neurosurgery and Psychiatry*, **2017**, 88, 474-483	5.5	58
237	Mouse models of frontotemporal dementia: A comparison of phenotypes with clinical symptomatology. *Neuroscience and Biobehavioral Reviews*, **2017**, 74, 126-138	9	18
236	Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Neurology, The*, **2017**, 16, 208-216	24.1	36
235	Peripheral nerve diffusion tensor imaging as a measure of disease progression in ALS. *Journal of Neurology*, **2017**, 264, 882-890	5.5	19
234	Physiological processes influencing motor-evoked potential duration with voluntary contraction. *Journal of Neurophysiology*, **2017**, 117, 1156-1162	3.2	19
233	Detection of fasciculations in amyotrophic lateral sclerosis: The optimal ultrasound scan time. *Muscle and Nerve*, **2017**, 56, 1068-1071	3.4	23
232	Author response: Diagnostic criteria in amyotrophic lateral sclerosis: A multicenter prospective study. *Neurology*, **2017**, 88, 719	6.5	1
231	Dynamic muscle ultrasound identifies upper motor neuron involvement in amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2017**, 18, 404-410	3.6	6
230	Fasciculation in amyotrophic lateral sclerosis: origin and pathophysiological relevance. *Journal of Neurology, Neurosurgery and Psychiatry*, **2017**, 88, 773-779	5.5	48
229	Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer. *Clinical Neurophysiology*, **2017**, 128, 1166-1175	4.3	32
228	Cortical function and corticomotoneuronal adaptation in monomelic amyotrophy. *Clinical Neurophysiology*, **2017**, 128, 1488-1495	4.3	7

227	Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. *Supportive Care in Cancer*, **2017**, 25, 3485-3493	3.9	45
226	The evolution of motor cortical dysfunction in amyotrophic lateral sclerosis. *Clinical Neurophysiology*, **2017**, 128, 1075-1082	4.3	18
225	The Effect of Diabetes on Cortical Function in Stroke: Implications for Poststroke Plasticity. *Diabetes*, **2017**, 66, 1661-1670	0.9	16
224	Some do not like it hot. *Journal of Physiology*, **2017**, 595, 3251-3252	3.9	2
223	The neural correlates and clinical characteristics of psychosis in the frontotemporal dementia continuum and the expansion. *NeuroImage: Clinical*, **2017**, 13, 439-445	5.3	35
222	Emerging therapies and challenges in spinal muscular atrophy. *Annals of Neurology*, **2017**, 81, 355-368	9.4	109
221	Cardiometabolic health and risk of amyotrophic lateral sclerosis. *Muscle and Nerve*, **2017**, 56, 721-725	3.4	4
220	Distinct TDP-43 inclusion morphologies in frontotemporal lobar degeneration with and without amyotrophic lateral sclerosis. *Acta Neuropathologica Communications*, **2017**, 5, 76	7.3	19
219	Sensory and motor axons are different: implications for neurological disease. *Annals of Clinical Neurophysiology*, **2017**, 19, 3	0.1	2
218	Randomized, Controlled Trial of the Effect of Dietary Potassium Restriction on Nerve Function in CKD. *Clinical Journal of the American Society of Nephrology: CJASN*, **2017**, 12, 1569-1577	6.9	32
217	Immune dysregulation in patients with carpal tunnel syndrome. *Scientific Reports*, **2017**, 7, 8218	4.9	8
216	Cortical influences drive amyotrophic lateral sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2017**, 88, 917-924	5.5	97
215	Motor unit remodelling in multifocal motor neuropathy: The importance of axonal loss. *Clinical Neurophysiology*, **2017**, 128, 2022-2028	4.3	20
214	Transcranial Magnetic Stimulation for the Assessment of Neurodegenerative Disease. *Neurotherapeutics*, **2017**, 14, 91-106	6.4	56
213	Energy expenditure in frontotemporal dementia: a behavioural and imaging study. *Brain*, **2017**, 140, 171-183	11.2	28
212	Laterality of motor cortical function measured by transcranial magnetic stimulation threshold tracking. *Muscle and Nerve*, **2017**, 55, 424-427	3.4	6
211	Haemodialysis alters peripheral nerve morphology in end-stage kidney disease. *Clinical Neurophysiology*, **2017**, 128, 281-286	4.3	10
210	Fampridine treatment and walking distance in multiple sclerosis: A randomised controlled trial. *Clinical Neurophysiology*, **2017**, 128, 93-99	4.3	6

209	Axonal Excitability in Amyotrophic Lateral Sclerosis : Axonal Excitability in ALS. *Neurotherapeutics*, **2017**, 14, 78-90	6.4	27
208	Motor neurone disease: progress and challenges. *Medical Journal of Australia*, **2017**, 206, 357-362	4	17
207	Cognitive and Behavioral Symptoms in ALSFTD: Detection, Differentiation, and Progression. *Journal of Geriatric Psychiatry and Neurology*, **2016**, 29, 3-10	3.8	20
206	Sleep disorders and respiratory function in amyotrophic lateral sclerosis. *Sleep Medicine Reviews*, **2016**, 26, 33-42	10.2	43
205	Pathophysiology of motor dysfunction in a childhood motor neuron disease caused by mutations in the riboflavin transporter. *Clinical Neurophysiology*, **2016**, 127, 911-918	4.3	18
204	Amyotrophic lateral sclerosis: moving towards a new classification system. *Lancet Neurology, The*, **2016**, 15, 1182-94	24.1	221
203	Diagnostic criteria in amyotrophic lateral sclerosis: A multicenter prospective study. *Neurology*, **2016**, 87, 684-90	6.5	31
202	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. *Nature Genetics*, **2016**, 48, 1043-8	36.3	328
201	Motor cortical function determines prognosis in sporadic ALS. *Neurology*, **2016**, 87, 513-20	6.5	54
200	Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy. *Brain and Behavior*, **2016**, 6, e00516	3.4	3
199	The Babinski sign. *Practical Neurology*, **2016**, 16, 419-20	2.4	1
198	Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis. *Expert Review of Neurotherapeutics*, **2016**, 16, 1147-54	4.3	14
197	Riluzole exerts transient modulating effects on cortical and axonal hyperexcitability in ALS. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2016**, 17, 580-588	3.6	44
196	Assessment of the upper motor neuron in amyotrophic lateral sclerosis. *Clinical Neurophysiology*, **2016**, 127, 2643-60	4.3	67
195	Assessment of Eating Behavior Disturbance and Associated Neural Networks in Frontotemporal Dementia. *JAMA Neurology*, **2016**, 73, 282-90	17.2	56
194	Amyotrophic lateral sclerosis and frontotemporal dementia: distinct and overlapping changes in eating behaviour and metabolism. *Lancet Neurology, The*, **2016**, 15, 332-42	24.1	88
193	Acute bulbar, neck and limb weakness with monospecific anti-GT1a antibody: A rare localized subtype of Guillain-Barr syndrome. *Muscle and Nerve*, **2016**, 53, 143-6	3.4	2
192	Threshold tracking transcranial magnetic stimulation: Effects of age and gender on motor cortical function. *Clinical Neurophysiology*, **2016**, 127, 2355-61	4.3	23

191	Cortical contributions to the flail leg syndrome: Pathophysiological insights. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2016**, 17, 389-96	3.6	17
190	The frontotemporal dementia-motor neuron disease continuum. *Lancet, The*, **2016**, 388, 919-31	40	191
189	Syntactic comprehension deficits across the FTD-ALS continuum. *Neurobiology of Aging*, **2016**, 41, 11-18	5.6	21
188	The Evolution of Caregiver Burden in Frontotemporal Dementia with and without Amyotrophic Lateral Sclerosis. *Journal of Alzheimeris Disease*, **2016**, 49, 875-85	4.3	20
187	My memories are important to me: Changes in autobiographical memory in amyotrophic lateral sclerosis. *Neuropsychology*, **2016**, 30, 920-930	3.8	4
186	Axonal damage in central and peripheral nervous system inflammatory demyelinating diseases: common and divergent pathways of tissue damage. *Current Opinion in Neurology*, **2016**, 29, 213-21	7.1	12
185	Comparative study to evaluate the effects of peritoneal and hemodialysis on peripheral nerve function. *Muscle and Nerve*, **2016**, 54, 58-64	3.4	6
184	Cerebellar neuronal loss in amyotrophic lateral sclerosis cases with ATXN2 intermediate repeat expansions. *Annals of Neurology*, **2016**, 79, 295-305	9.4	21
183	Neuronal network disintegration: common pathways linking neurodegenerative diseases. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 1234-1241	5.5	69
182	Treatment approaches in motor neurone disease. *Current Opinion in Neurology*, **2016**, 29, 581-91	7.1	10
181	TDP-43 in the hypoglossal nucleus identifies amyotrophic lateral sclerosis in behavioral variant frontotemporal dementia. *Journal of the Neurological Sciences*, **2016**, 366, 197-201	3.2	9
180	In vivo evidence of reduced nodal and paranodal conductances in type 1 diabetes. *Clinical Neurophysiology*, **2016**, 127, 1700-1706	4.3	15
179	Advance care planning in motor neuron disease: A qualitative study of caregiver perspectives. *Palliative Medicine*, **2016**, 30, 471-8	5.5	28
178	Effect of fampridine on axonal excitability in multiple sclerosis. *Clinical Neurophysiology*, **2016**, 127, 2636-42	4.3	8
177	Awaji criteria improves the diagnostic sensitivity in amyotrophic lateral sclerosis: A systematic review using individual patient data. *Clinical Neurophysiology*, **2016**, 127, 2684-91	4.3	49
176	Motor cortical dysfunction develops in spinocerebellar ataxia type 3. *Clinical Neurophysiology*, **2016**, 127, 3418-3424	4.3	16
175	Pathophysiological and diagnostic implications of cortical dysfunction in ALS. *Nature Reviews Neurology*, **2016**, 12, 651-661	15	119
174	Potential structural and functional biomarkers of upper motor neuron dysfunction in ALS. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2015**, 17, 85-92	3.6	25

173	TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes. *Brain*, **2015**, 138, 3110-22	11.2	66
172	Precise correlation between structural and electrophysiological disturbances in MADSAM neuropathy. *Neuromuscular Disorders*, **2015**, 25, 904-7	2.9	13
171	Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study. *Lancet Neurology, The*, **2015**, 14, 478-84	24.1	124
170	Semantic deficits in amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2015**, 16, 46-53	3.6	31
169	Motor neuron disease-frontotemporal dementia: a clinical continuum. *Expert Review of Neurotherapeutics*, **2015**, 15, 509-22	4.3	41
168	Dissociated lower limb muscle involvement in amyotrophic lateral sclerosis. *Journal of Neurology*, **2015**, 262, 1424-32	5.5	31
167	Development of a model to guide decision making in amyotrophic lateral sclerosis multidisciplinary care. *Health Expectations*, **2015**, 18, 1769-82	3.7	21
166	Palliative care in amyotrophic lateral sclerosis. *Lancet Neurology, The*, **2015**, 14, 347-8	24.1	6
165	Short-term peripheral nerve stimulation ameliorates axonal dysfunction after spinal cord injury. *Journal of Neurophysiology*, **2015**, 113, 3209-18	3.2	18
164	Kidney-brain crosstalk in the acute and chronic setting. *Nature Reviews Nephrology*, **2015**, 11, 707-19	14.9	115
163	Cortical Function in Asymptomatic Carriers and Patients With C9orf72 Amyotrophic Lateral Sclerosis. *JAMA Neurology*, **2015**, 72, 1268-74	17.2	59
162	Eating behavior in frontotemporal dementia: Peripheral hormones vs hypothalamic pathology. *Neurology*, **2015**, 85, 1310-7	6.5	57
161	Segmental motoneuronal dysfunction is a feature of amyotrophic lateral sclerosis. *Clinical Neurophysiology*, **2015**, 126, 828-36	4.3	19
160	The Genetics of Spinal Muscular Atrophy: Progress and Challenges. *Neurotherapeutics*, **2015**, 12, 290-302	6.4	62
159	Cortical hyperexcitability precedes lower motor neuron dysfunction in ALS. *Clinical Neurophysiology* , **2015**, 126, 803-9	4.3	98
158	A longer diagnostic interval is a risk for depression in amyotrophic lateral sclerosis. *Palliative and Supportive Care*, **2015**, 13, 1019-24	2.5	24
157	Characterizing Sexual Behavior in Frontotemporal Dementia. *Journal of Alzheimeris Disease*, **2015**, 46, 677-86	4.3	27
156	Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial. *EBioMedicine*, **2015**, 2, 1916-22	8.8	20

155	Quantitative ultrasound of denervated hand muscles. *Muscle and Nerve*, **2015**, 52, 221-30	3.4	28
154	Terra incognita-cerebellar contributions to neuropsychiatric and cognitive dysfunction in behavioral variant frontotemporal dementia. *Frontiers in Aging Neuroscience*, **2015**, 7, 121	5.3	19
153	Axonal ion channel dysfunction in c9orf72 familial amyotrophic lateral sclerosis. *JAMA Neurology*, **2015**, 72, 49-57	17.2	27
152	Lou Gehrig and the ALS split hand. *Neurology*, **2015**, 85, 1995	6.5	4
151	Does dysfunction of the mirror neuron system contribute to symptoms in amyotrophic lateral sclerosis?. *Clinical Neurophysiology*, **2015**, 126, 1288-94	4.3	12
150	Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, 973-85	5.5	243
149	Progressive bilateral facial weakness. *Practical Neurology*, **2015**, 15, 76-9	2.4	5
148	Continuous subcutaneous insulin infusion preserves axonal function in type 1 diabetes mellitus. *Diabetes/Metabolism Research and Reviews*, **2015**, 31, 175-82	7.5	13
147	ALS pathophysiology: insights from the split-hand phenomenon. *Clinical Neurophysiology*, **2014**, 125, 186-93	4.3	31
146	Emotion processing deficits distinguish pure amyotrophic lateral sclerosis from frontotemporal dementia. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2014**, 15, 39-46	3.6	37
145	Guillain-Barr□syndrome in Asia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2014**, 85, 907-13	5.5	40
144	Patterns of clinical and electrodiagnostic abnormalities in early amyotrophic lateral sclerosis. *Muscle and Nerve*, **2014**, 50, 894-9	3.4	28
143	Early identification of 'acute-onset' chronic inflammatory demyelinating polyneuropathy. *Brain*, **2014**, 137, 2155-63	11.2	23
142	Quantifying disease progression in amyotrophic lateral sclerosis. *Annals of Neurology*, **2014**, 76, 643-57	9.4	102
141	Axonal dysfunction, dysmyelination, and conduction failure in hereditary neuropathy with liability to pressure palsies. *Muscle and Nerve*, **2014**, 49, 858-65	3.4	10
140	Frontotemporal dementia associated with the C9ORF72 mutation: a unique clinical profile. *JAMA Neurology*, **2014**, 71, 331-9	17.2	112
139	Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies. *Trends in Neurosciences*, **2014**, 37, 433-42	13.3	150
138	Axonal dysfunction with voltage gated potassium channel complex antibodies. *Experimental Neurology*, **2014**, 261, 337-42	5.7	11

137	ALS and neuromuscular disease: in search of the Holy Grail. *Lancet Neurology, The*, **2014**, 13, 13-4	24.1	7
136	Cortical dysfunction underlies the development of the split-hand in amyotrophic lateral sclerosis. *PLoS ONE*, **2014**, 9, e87124	3.7	55
135	Apraxia and motor dysfunction in corticobasal syndrome. *PLoS ONE*, **2014**, 9, e92944	3.7	23
134	Cerebellar integrity in the amyotrophic lateral sclerosis-frontotemporal dementia continuum. *PLoS ONE*, **2014**, 9, e105632	3.7	60
133	A visual MRI atrophy rating scale for the amyotrophic lateral sclerosis-frontotemporal dementia continuum. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2014**, 15, 226-34	3.6	24
132	Neuropsychiatric changes precede classic motor symptoms in ALS and do not affect survival. *Neurology*, **2014**, 82, 149-55	6.5	79
131	Cortical excitability differences in hand muscles follow a split-hand pattern in healthy controls. *Muscle and Nerve*, **2014**, 49, 836-44	3.4	17
130	Study of motor asymmetry in ALS indicates an effect of limb dominance on onset and spread of weakness, and an important role for upper motor neurons. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2014**, 15, 481-7	3.6	39
129	Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypes. *BMC Cancer*, **2014**, 14, 993	4.8	17
128	Systemic metabolism in frontotemporal dementia. *Neurology*, **2014**, 83, 1812-8	6.5	40
127	A novel tool to detect behavioural symptoms in ALS. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2014**, 15, 298-304	3.6	42
126	Evidence for a causal relationship between hyperkalaemia and axonal dysfunction in end-stage kidney disease. *Clinical Neurophysiology*, **2014**, 125, 179-85	4.3	33
125	Cortical dysfunction in cerebellar ataxia with antibodies to glutamic acid decarboxylase. *Journal of Neurology*, **2014**, 261, 238-9	5.5	1
124	Neurotoxicity and ALS: Insights into Pathogenesis **2014**, 1435-1456		
123	Fasciculation anxiety syndrome in clinicians. *Journal of Neurology*, **2013**, 260, 1743-7	5.5	19
122	Physiology and pathophysiology of myelinated nerve fibers. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2013**, 115, 43-53	3	13
121	Utility of transcranial magnetic stimulation in delineating amyotrophic lateral sclerosis pathophysiology. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2013**, 116, 561-75	3	28
120	Controversies and priorities in amyotrophic lateral sclerosis. *Lancet Neurology, The*, **2013**, 12, 310-22	24.1	377

119	Split-hand plus sign in ALS: differential involvement of the flexor pollicis longus and intrinsic hand muscles. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2013**, 14, 315-8	3.6	31
118	Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy. *Journal of Pediatrics*, **2013**, 162, 155-9	3.6	73
117	Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights. *Journal of Neurology, Neurosurgery and Psychiatry*, **2013**, 84, 1161-70	5.5	167
116	Axonal dysfunction prior to neuropathy onset in type 1 diabetes. *Diabetes/Metabolism Research and Reviews*, **2013**, 29, 53-9	7.5	27
115	Pathophysiological insights into ALS with C9ORF72 expansions. *Journal of Neurology, Neurosurgery and Psychiatry*, **2013**, 84, 931-5	5.5	80
114	Split-hand index for the diagnosis of amyotrophic lateral sclerosis. *Clinical Neurophysiology*, **2013**, 124, 410-6	4.3	66
113	Evolution of peripheral nerve function in humans: novel insights from motor nerve excitability. *Journal of Physiology*, **2013**, 591, 273-86	3.9	19
112	Botulinum toxin modulates cortical maladaptation in post-stroke spasticity. *Muscle and Nerve*, **2013** , 48, 93-9	3.4	19
111	Cortical atrophy in ALS is critically associated with neuropsychiatric and cognitive changes. *Neurology*, **2013**, 80, 1117-23	6.5	80
110	Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. *Brain*, **2013**, 136, 1361-70	11.2	102
109	Chemotherapy-induced peripheral neurotoxicity: a critical analysis. *Ca-A Cancer Journal for Clinicians*, **2013**, 63, 419-37	220.7	410
108	Effects of axonal ion channel dysfunction on quality of life in type 2 diabetes. *Diabetes Care*, **2013**, 36, 1272-7	14.6	28
107	What are the roles of carers in decision-making for amyotrophic lateral sclerosis multidisciplinary care?. *Patient Preference and Adherence*, **2013**, 7, 171-81	2.4	41
106	Effects of hemodiafiltration and high flux hemodialysis on nerve excitability in end-stage kidney disease. *PLoS ONE*, **2013**, 8, e59055	3.7	15
105	The puzzling case of hyperexcitability in amyotrophic lateral sclerosis. *Journal of Clinical Neurology (Korea*, **2013**, 9, 65-74	1.7	91
104	Nerve Excitability: A Clinical Translation **2012**, 345-365		6
103	In vivo loss of slow potassium channel activity in individuals with benign familial neonatal epilepsy in remission. *Brain*, **2012**, 135, 3144-52	11.2	14
102	Does interneuronal dysfunction contribute to neurodegeneration in amyotrophic lateral sclerosis?. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2012**, 13, 245-50		104

101	Impact of oxaliplatin-induced neuropathy: a patient perspective. *Supportive Care in Cancer*, **2012**, 20, 2959-67	3.9	76
100	Emergence of a predictive clinical biomarker for diabetic neuropathy. *Diabetes*, **2012**, 61, 1346-7	0.9	4
99	Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis. *Clinical Neurophysiology*, **2012**, 123, 2460-7	4.3	35
98	Amyotrophic lateral sclerosis and frontotemporal dementia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2012**, 83, 355	5.5	3
97	Grey and white matter changes across the amyotrophic lateral sclerosis-frontotemporal dementia continuum. *PLoS ONE*, **2012**, 7, e43993	3.7	139
96	Amyotrophic lateral sclerosis and frontotemporal dementia: A behavioural and cognitive continuum. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2012**, 13, 102-9		107
95	FOSMN syndrome: novel insight into disease pathophysiology. *Neurology*, **2012**, 79, 73-9	6.5	35
94	Response to Karam et al.. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2012**, 13, 159-160		
93	Spinal Muscular Atrophy **2011**,		1
92	Clinical diagnosis and management of amyotrophic lateral sclerosis. *Nature Reviews Neurology*, **2011**, 7, 639-49	15	398
91	Regional differences in ulnar nerve excitability may predispose to the development of entrapment neuropathy. *Clinical Neurophysiology*, **2011**, 122, 194-8	4.3	6
90	Purple pigments: the pathophysiology of acute porphyric neuropathy. *Clinical Neurophysiology*, **2011**, 122, 2336-44	4.3	34
89	Isolated bulbar phenotype of amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2011**, 12, 283-9		44
88	Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy. *Experimental Neurology*, **2011**, 227, 120-7	5.7	14
87	Cortical excitability distinguishes ALS from mimic disorders. *Clinical Neurophysiology*, **2011**, 122, 1860-6	4.3	101
86	Amyotrophic lateral sclerosis. *Lancet, The*, **2011**, 377, 942-55	40	1665
85	Appearance, phenomenology and diagnostic utility of the split hand in amyotrophic lateral sclerosis. *Neurodegenerative Disease Management*, **2011**, 1, 457-462	2.8	9
84	The contribution of SK3 polymorphisms to acute oxaliplatin-induced neurotoxicity: direct or indirect effects?. *Cancer Chemotherapy and Pharmacology*, **2011**, 67, 1189-90; author reply 1191-2	3.5	2

83	Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. *Muscle and Nerve*, **2011**, 43, 367-74	3.4	52
82	Nerve compression, membrane excitability, and symptoms of carpal tunnel syndrome. *Muscle and Nerve*, **2011**, 44, 402-9	3.4	11
81	The effects of large artery ischemia and subsequent recanalization on nerve excitability. *Muscle and Nerve*, **2011**, 44, 841-2	3.4	7
80	Maladaptation of cortical circuits underlies fatigue and weakness in ALS. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2011**, 12, 414-20		15
79	Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. *Archives of Neurology*, **2011**, 68, 862-9		46
78	Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. *Oncologist*, **2011**, 16, 708-16	5.7	148
77	Adaptation of motor function after spinal cord injury: novel insights into spinal shock. *Brain*, **2011**, 134, 495-505	11.2	26
76	Motor neuron dysfunction in frontotemporal dementia. *Brain*, **2011**, 134, 2582-94	11.2	219
75	Dysfunction of axonal membrane conductances in adolescents and young adults with spinal muscular atrophy. *Brain*, **2011**, 134, 3185-97	11.2	25
74	How common are behavioural changes in amyotrophic lateral sclerosis?. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2011**, 12, 45-51		138
73	Dissecting the mechanisms underlying short-interval intracortical inhibition using exercise. *Cerebral Cortex*, **2011**, 21, 1639-44	5.1	25
72	Neurophysiological index as a biomarker for ALS progression: validity of mixed effects models. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2011**, 12, 33-8		41
71	Predicting a positive response to intravenous immunoglobulin in isolated lower motor neuron syndromes. *PLoS ONE*, **2011**, 6, e27041	3.7	12
70	Changes in human sensory axonal excitability induced by focal nerve compression. *Journal of Physiology*, **2010**, 588, 1737-45	3.9	19
69	Upregulation of persistent sodium conductances in familial ALS. *Journal of Neurology, Neurosurgery and Psychiatry*, **2010**, 81, 222-7	5.5	63
68	Corticomotoneuronal function and hyperexcitability in acquired neuromyotonia. *Brain*, **2010**, 133, 2727-33	11.2	27
67	FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2010**, 81, 639-45	5.5	177
66	Chemotherapy-Induced Neurotoxicity **2010**, 99-119		

65	Corticospinal tract dysfunction and development of amyotrophic lateral sclerosis following electrical injury. *Muscle and Nerve*, **2010**, 42, 288-92	3.4	11
64	Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. *Journal of Clinical Oncology*, **2009**, 27, 1243-9	2.2	125
63	The effects of alterations in conditioning stimulus intensity on short interval intracortical inhibition. *Brain Research*, **2009**, 1273, 39-47	3.7	55
62	Biomarkers in amyotrophic lateral sclerosis. *Lancet Neurology, The*, **2009**, 8, 94-109	24.1	340
61	Threshold behaviour of human axons explored using subthreshold perturbations to membrane potential. *Journal of Physiology*, **2009**, 587, 491-504	3.9	21
60	Amyotrophic lateral sclerosis and the neuroprotective potential of exercise. *Journal of Physiology*, **2009**, 587, 3759-60	3.9	7
59	Ischaemic sensitivity of axons in carpal tunnel syndrome. *Journal of the Peripheral Nervous System*, **2009**, 14, 190-200	4.7	24
58	Hyperexcitability, persistent Na+ conductances and neurodegeneration in amyotrophic lateral sclerosis. *Experimental Neurology*, **2009**, 218, 1-4	5.7	18
57	Axonal ion channels from bench to bedside: a translational neuroscience perspective. *Progress in Neurobiology*, **2009**, 89, 288-313	10.9	131
56	Plasticity of lower limb motor axons after cervical cord injury. *Clinical Neurophysiology*, **2009**, 120, 204-9	4.3	22
55	Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. *Brain*, **2009**, 132, 2712-23	11.2	155
54	Defining the mechanisms that underlie cortical hyperexcitability in amyotrophic lateral sclerosis. *Experimental Neurology*, **2009**, 220, 177-82	5.7	58
53	Cortical excitability testing distinguishes Kennedy's disease from amyotrophic lateral sclerosis. *Clinical Neurophysiology*, **2008**, 119, 1088-96	4.3	58
52	Activity-dependent excitability changes suggest Na+/K+ pump dysfunction in diabetic neuropathy. *Brain*, **2008**, 131, 1209-16	11.2	72
51	Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. *Brain*, **2008**, 131, 1540-50	11.2	307
50	Nerve function and dysfunction in acute intermittent porphyria. *Brain*, **2008**, 131, 2510-9	11.2	66
49	Inflections in threshold electrotonus to depolarizing currents in sensory axons. *Muscle and Nerve*, **2007**, 36, 849-52	3.4	6
48	Axonal changes in spinal cord injured patients distal to the site of injury. *Brain*, **2007**, 130, 985-94	11.2	76

47	Pathophysiologic insights into motor axonal function in Kennedy disease. *Neurology*, **2007**, 69, 1828-35	6.5	22
46	Abnormalities in cortical and peripheral excitability in flail arm variant amyotrophic lateral sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2007**, 78, 849-52	5.5	75
45	Fatigue and activity dependent changes in axonal excitability in amyotrophic lateral sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2007**, 78, 1202-8	5.5	44
44	Assessment of cortical excitability using threshold tracking techniques. *Muscle and Nerve*, **2006**, 33, 477-86	3.4	137
43	Ischaemia induces paradoxical changes in axonal excitability in end-stage kidney disease. *Brain*, **2006**, 129, 1585-92	11.2	22
42	The pathophysiology of oxaliplatin-induced neurotoxicity. *Current Medicinal Chemistry*, **2006**, 13, 2901-7	4.3	35
41	Oxaliplatin and axonal Na+ channel function in vivo. *Clinical Cancer Research*, **2006**, 12, 4481-4	12.9	68
40	Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. *Brain*, **2006**, 129, 2436-46	11.2	227
39	Neuropathy, axonal Na+/K+ pump function and activity-dependent excitability changes in end-stage kidney disease. *Clinical Neurophysiology*, **2006**, 117, 992-9	4.3	30
38	Axonal excitability properties in amyotrophic lateral sclerosis. *Clinical Neurophysiology*, **2006**, 117, 1458-66	4.3	145
37	Riluzole therapy for motor neurone disease: an early Australian experience (1996-2002). *Journal of Clinical Neuroscience*, **2006**, 13, 78-83	2.2	27
36	Chapter 17 Assessment of nerve excitability properties in peripheral nerve disease. *Handbook of Clinical Neurophysiology*, **2006**, 7, 381-403		11
35	Altered nerve excitability properties in established diabetic neuropathy. *Brain*, **2005**, 128, 1178-87	11.2	101
34	Altered motor nerve excitability in end-stage kidney disease. *Brain*, **2005**, 128, 2164-74	11.2	95
33	Assessment of disease progression in motor neuron disease. *Lancet Neurology, The*, **2005**, 4, 229-38	24.1	62
32	Acute tetrodotoxin-induced neurotoxicity after ingestion of puffer fish. *Annals of Neurology*, **2005**, 57, 339-48	9.4	145
31	Excitability differences in lower-limb motor axons during and after ischemia. *Muscle and Nerve*, **2005**, 31, 205-13	3.4	13
30	Oxaliplatin-induced neurotoxicity and the development of neuropathy. *Muscle and Nerve*, **2005**, 32, 51-60	3.4	170

29	Nerve Excitability Measures: Biophysical Basis and Use in the Investigation of Peripheral Nerve Disease **2005**, 113-129		16
28	Riluzole: a glimmer of hope in the treatment of motor neurone disease. *Medical Journal of Australia* , **2005**, 183, 164-165	4	
27	Mutation in the Na+ channel subunit SCN1B produces paradoxical changes in peripheral nerve excitability. *Brain*, **2005**, 128, 1841-6	11.2	51
26	Differences in activity-dependent hyperpolarization in human sensory and motor axons. *Journal of Physiology*, **2004**, 558, 341-9	3.9	112
25	Nerve excitability properties in lower-limb motor axons: evidence for a length-dependent gradient. *Muscle and Nerve*, **2004**, 29, 645-55	3.4	37
24	Mitochondrial dysfunction and rod-like lesions associated with administration of beta2 adrenoceptor agonist formoterol. *Neuromuscular Disorders*, **2004**, 14, 375-7	2.9	3
23	Threshold electrotonus and the assessment of nerve excitability in amyotrophic lateral sclerosis. *Handbook of Clinical Neurophysiology*, **2004**, 4, 359-366		4
22	Impulse Conduction **2003**, 639-642		
21	Evidence for axonal membrane hyperpolarization in multifocal motor neuropathy with conduction block. *Brain*, **2002**, 125, 664-75	11.2	148
20	Nerve excitability changes in chronic renal failure indicate membrane depolarization due to hyperkalaemia. *Brain*, **2002**, 125, 1366-78	11.2	111
19	Chapter 23 Pathophysiology of paraesthesiae. *Supplements To Clinical Neurophysiology*, **2002**, 54, 156-162		
18	Clinical evaluation of excitability measures in sensory nerve. *Muscle and Nerve*, **2001**, 24, 883-92	3.4	128
17	Distal excitability properties of median motor axons. *Muscle and Nerve*, **2001**, 24, 1695-8	3.4	8
16	Excitability of human axons. *Clinical Neurophysiology*, **2001**, 112, 1575-85	4.3	339
15	Clinical evaluation of excitability measures in sensory nerve **2001**, 24, 883		1
14	Multiple measures of axonal excitability: a new approach in clinical testing. *Muscle and Nerve*, **2000**, 23, 399-409	3.4	352
13	Conduction block in carpal tunnel syndrome. *Brain*, **1999**, 122 (Pt 5), 933-41	11.2	62
12	Temperature dependence of excitability indices of human cutaneous afferents. *Muscle and Nerve*, **1999**, 22, 51-60	3.4	60

11	Heat sensitivity of sensory fibers in carpal tunnel syndrome. *Muscle and Nerve*, **1999**, 22, 969-70	3.4	2
10	Monomelic amyotrophy: non progressive atrophy of the upper limb. *Journal of Clinical Neuroscience* , **1999**, 6, 353-355	2.2	8
9	Activity-dependent hyperpolarization of human motor axons produced by natural activity. *Journal of Physiology*, **1998**, 507 (Pt 3), 919-25	3.9	166
8	Ischemic resistance of cutaneous afferents and motor axons in patients with amyotrophic lateral sclerosis. *Muscle and Nerve*, **1998**, 21, 1692-700	3.4	14
7	Paraesthesiae induced by prolonged high frequency stimulation of human cutaneous afferents. *Journal of Physiology*, **1997**, 501 (Pt 2), 461-71	3.9	27
6	Changes in excitability and impulse transmission following prolonged repetitive activity in normal subjects and patients with a focal nerve lesion. *Brain*, **1996**, 119 (Pt 6), 2029-37	11.2	30
5	Strength-duration properties of human peripheral nerve. *Brain*, **1996**, 119 (Pt 2), 439-47	11.2	272
4	IBD analysis of Australian amyotrophic lateral sclerosis SOD1-mutation carriers identifies five founder events and links sporadic cases to existing ALS families		2
3	Genome-wide study of DNA methylation in Amyotrophic Lateral Sclerosis identifies differentially methylated loci and implicates metabolic, inflammatory and cholesterol pathways		1
2	Cortical hyperexcitability drives dying forward ALS symptoms and pathology in mice		2
1	Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use. *Quality of Life Research*,	3.7	0